Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer. [electronic resource]
Producer: 20160412Description: e1850 p. digitalISSN:- 2041-4889
- Adenocarcinoma -- drug therapy
- Aged
- Animals
- Antineoplastic Agents -- pharmacology
- Apoptosis -- drug effects
- Biomarkers, Pharmacological -- metabolism
- Carcinoma, Non-Small-Cell Lung -- drug therapy
- Carcinoma, Squamous Cell -- drug therapy
- Cell Line, Tumor
- Drug Evaluation, Preclinical
- ErbB Receptors -- genetics
- Erlotinib Hydrochloride -- pharmacology
- Female
- Gene Expression Regulation, Neoplastic
- Humans
- Lung Neoplasms -- drug therapy
- Male
- Mice
- Mice, SCID
- Middle Aged
- Neoplasm Staging
- Neoplastic Stem Cells -- drug effects
- Phosphorylation -- drug effects
- Protein Kinase Inhibitors -- pharmacology
- Proto-Oncogene Proteins p21(ras) -- genetics
- Receptor, ErbB-2 -- genetics
- Signal Transduction
- Tyrosine -- metabolism
- Xenograft Model Antitumor Assays
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.